248 related articles for article (PubMed ID: 7816256)
1. Treatment of aluminium intoxication: a new scheme for desferrioxamine administration.
Douthat WG; Acuña Aguerre G; Fernández Martín JL; Mouzo R; Cannata Andía JB
Nephrol Dial Transplant; 1994; 9(10):1431-4. PubMed ID: 7816256
[TBL] [Abstract][Full Text] [Related]
2. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules.
Barata JD; D'Haese PC; Pires C; Lamberts LV; Simões J; De Broe ME
Nephrol Dial Transplant; 1996 Jan; 11(1):125-32. PubMed ID: 8649620
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with desferrioxamine in dialysis patients with aluminium toxicity.
McCarthy JT; Milliner DS; Johnson WJ
Q J Med; 1990 Mar; 74(275):257-76. PubMed ID: 2117295
[TBL] [Abstract][Full Text] [Related]
4. Haemofiltration or haemodialysis in aluminium elimination?
Sulkova S; Laurincova Z; Válek A
Nephrol Dial Transplant; 1991; 6 Suppl 3():3-5. PubMed ID: 1775263
[TBL] [Abstract][Full Text] [Related]
5. Desferrioxamine-induced changes of aluminium kinetics during haemodialysis.
Graf H; Stummvoll HK; Meisinger V
Proc Eur Dial Transplant Assoc; 1981; 18():674-80. PubMed ID: 7329995
[TBL] [Abstract][Full Text] [Related]
6. Desferrioxamine in the treatment of aluminum overload.
Ackrill P; Day JP
Clin Nephrol; 1985; 24 Suppl 1():S94-7. PubMed ID: 3842106
[TBL] [Abstract][Full Text] [Related]
7. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload.
D'Haese PC; Couttenye MM; Goodman WG; Lemoniatou E; Digenis P; Sotornik I; Fagalde A; Barsoum RS; Lamberts LV; De Broe ME
Nephrol Dial Transplant; 1995 Oct; 10(10):1874-84. PubMed ID: 8592597
[TBL] [Abstract][Full Text] [Related]
8. [Aluminum poisoning in dialysis patients--diagnosis and therapy].
Vogelsang U
Schweiz Rundsch Med Prax; 1994 Jun; 83(24):738-56. PubMed ID: 8023059
[TBL] [Abstract][Full Text] [Related]
9. [Detecting and evaluating hyperaluminemia in 3 dialysis centers].
Balabán D; Simícková J; Kubátko J; Syrovátka P
Cas Lek Cesk; 1989 Dec; 128(51):1611-4. PubMed ID: 2631999
[TBL] [Abstract][Full Text] [Related]
10. Comparison of low-dose deferoxamine versus standard-dose deferoxamine for treatment of aluminium overload among haemodialysis patients.
Kan WC; Chien CC; Wu CC; Su SB; Hwang JC; Wang HY
Nephrol Dial Transplant; 2010 May; 25(5):1604-8. PubMed ID: 19948879
[TBL] [Abstract][Full Text] [Related]
11. Ultrafiltrable aluminium after very low doses of desferrioxamine.
Canteros A; Díaz-Corte C; Fernández-Martín JL; Gago E; Fernández-Merayo C; Cannata J
Nephrol Dial Transplant; 1998 Jun; 13(6):1538-42. PubMed ID: 9641189
[TBL] [Abstract][Full Text] [Related]
12. Desferrioxamine induced aluminium removal in haemodialysis.
Bonal J; Montoliu J; Löpez Pedret J; Bergadä E; Andrew L; Bachs M; Revert L
Proc Eur Dial Transplant Assoc Eur Ren Assoc; 1985; 21():366-70. PubMed ID: 3991524
[TBL] [Abstract][Full Text] [Related]
13. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
14. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
[TBL] [Abstract][Full Text] [Related]
15. Risk of aluminium intoxication in long-term acetate Redy dialysis.
Van de Vyver FL; Visser WJ; D'Haese PC; Silva FJ; Thomas H; De Broe ME
Nephrol Dial Transplant; 1989; 4(6):555-62. PubMed ID: 2507978
[TBL] [Abstract][Full Text] [Related]
16. Plasma aluminium: a redundant test for patients on dialysis?
Gault PM; Allen KR; Newton KE
Ann Clin Biochem; 2005 Jan; 42(Pt 1):51-4. PubMed ID: 15802033
[TBL] [Abstract][Full Text] [Related]
17. [Aluminum osteopathy--experience with therapy].
Sulková S
Vnitr Lek; 1993 May; 39(5):459-63. PubMed ID: 8351877
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of serum aluminium levels for bone accumulation in haemodialyzed patients.
Costantini S; Giordano R; Vernillo I; Piccioni A; Zapponi GA
Ann Ist Super Sanita; 1989; 25(3):457-61. PubMed ID: 2624356
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of long-term and low-dose desferrioxamine therapy against hyperaluminemia and the clinical symptoms associated with hyperaluminemia in patients undergoing maintenance hemodialysis].
Kuramochi G
Nihon Jinzo Gakkai Shi; 1989 Mar; 31(3):267-73. PubMed ID: 2739124
[TBL] [Abstract][Full Text] [Related]
20. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine.
Lillevang ST; Pedersen FB
Nephrol Dial Transplant; 1989; 4(7):676. PubMed ID: 2510071
[No Abstract] [Full Text] [Related]
[Next] [New Search]
